TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

This study is testing a combination of two treatments — TATE (a type of liver-directed therapy) and pembrolizumab (an immunotherapy drug) — for patients with colorectal cancer that has spread to the liver (MSS subtype) or non-small cell lung cancer that has stopped responding to standard therapy. **You may be eligible if...** - You have metastatic colorectal cancer (MSS type) that has spread to the liver and progressed on at least 2 prior chemotherapy regimens, OR non-small cell lung cancer that has progressed on chemotherapy and immunotherapy - Your cancer is measurable on imaging - Your general health is good (ECOG 0-1) - It has been at least 4 weeks since your last chemotherapy **You may NOT be eligible if...** - You have had a prior organ transplant - More than 50% of your liver is involved with cancer - Your oxygen levels are low (below 92% in room air) - You have significant heart or autoimmune conditions Talk to your doctor to see if this trial is right for you.